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ABSTRACT
Introduction: Solitary pulmonary nodules (SPNs) are
common on CT. The most cost-effective investigation
algorithm is still to be determined. Dynamic contrast-
enhanced CT (DCE-CT) is an established diagnostic
test not widely available in the UK currently.
Methods and analysis: The SPUtNIk study will
assess the diagnostic accuracy, clinical utility and cost-
effectiveness of DCE-CT, alongside the current CT and
18-flurodeoxyglucose-positron emission tomography)
(18FDG-PET)-CT nodule characterisation strategies in
the National Health Service (NHS). Image acquisition
and data analysis for 18FDG-PET-CT and DCE-CT will
follow a standardised protocol with central review of
10% to ensure quality assurance. Decision analytic
modelling will assess the likely costs and health
outcomes resulting from incorporation of DCE-CT into
management strategies for patients with SPNs.
Ethics and dissemination: Approval has been
granted by the South West Research Ethics Committee.
Ethics reference number 12/SW/0206. The results of
the trial will be presented at national and international
meetings and published in an Health Technology
Assessment (HTA) Monograph and in peer-reviewed
journals.
Trial registration number: ISRCTN30784948;
Pre-results.
BACKGROUND
Solitary pulmonary nodule (SPN) is deﬁned
as a discrete well-deﬁned intraparenchymal
lesion <3 cm. SPNs are present in 20–50% of
individuals considered to be at high risk for
lung cancer and present an important diag-
nostic problem. A small proportion of
patients with a SPN will have early stage lung
cancer with a high 5-year survival rate
following surgical resection. In the National
Lung Screening Trial (NLST) an SPN was
identiﬁed in 24% of the 53 454 asymptomatic
current or former smokers with a 30 pack
year history and of these >95% were benign.
CT is the ﬁrst-line investigation for SPN.
Fleischner Society guidelines have been
widely used for many years although recently
published British Thoracic Society (BTS)
guidelines using the prediction scores and
volumetry are now being more widely used
in the UK. In general, nodules of 8 mm or
less in diameter are assessed for interval
growth using serial CT surveillance. For
nodules >8 mm a number of imaging
options are available determined by the
patient’s performance status and the prob-
ability for malignancy. For patients that are
potentially suitable for treatment with cura-
tive intent, positron emission tomography-CT
(PET-CT) is the investigation of choice.
PET-CT provides both anatomical (CT) and
functional information (PET) following intra-
venous administration of small quantities of
the radioactive glucose analogue
18-ﬂurodeoxyglucose (18FDG). 18FDG-PET
characterises SPNs on the basis of increased
glucose metabolism in malignant lesions.
However, false positives can occur in certain
benign conditions including granulomatous
disease and infective/inﬂammatory lesions.
False-negative scans are seen in tumours with
low glucose metabolism including lung
adenocarcinoma with a lepidic or mucinous
component and carcinoid tumours with no
atypia. In order to minimise patient anxiety,
risk of overdiagnosis, cumulative radiation
burden and cost of performing multiple tests
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a streamlined diagnostic pathway that involves the least
number of investigations for accurate nodule character-
isation is essential. In Paul Barnett’s study looking at the
management of patients with SPNs for the Veterans
Affairs Positron Emission Tomography Imaging
Cooperative study group, the average US Medicare
expenditure for clinical management of an incidental
SPN was $50 233 (£30 363) when the nodule was malig-
nant and $22 461 (£13 577) when benign.
Dynamic contrast-enhanced CT (DCE-CT) is an
imaging technique that involves the acquisition of a
series of CT images through the nodule before and at
ﬁxed time points after the injection of an iodinated con-
trast medium. A region of interest is placed within the
nodule and the mean enhancement value (Hounsﬁeld
Units) is calculated at each time point. DCE-CT charac-
terises SPNs on the basis of increased enhancement in
malignant nodules reﬂecting the presence of tumour
neovascularisation. Malignant nodules typically demon-
strate increased contrast enhancement >15 HU com-
pared with benign nodules.
Pooled analysis from 10 DCE-CT studies (incorporat-
ing 1167 nodules) reported a sensitivity, speciﬁcity, PPV
and NPV of 93%, 76%, 80% and 95%, respectively, for
differentiating malignant from benign nodules.1 A
single study that compared the relative cost-effectiveness
of DCE-CT to conventional CT surveillance and
PET-based strategies for nodule evaluation, demon-
strated savings of up to £2000 per patient compared with
routine nodule surveillance. Furthermore, a strategy
whereby patients only underwent 18FDG-PET if DCE-CT
suggested malignancy had similar effectiveness to
18FDG-PET alone but was consistently less expensive.2
To date, only three studies have directly compared the
diagnostic performances of 18FDG-PET and DCE-CT in
the same cohort of patients. However, pooled data from
these three studies evaluating 217 SPNs demonstrated
that 18FDG-PET and DCE-CT had sensitivities of 92%
and 87% and speciﬁcities of 90% and 83%,
respectively.3–5 As yet, no large comparative multicentre
trial of DCE-CT as a standalone technique or in combin-
ation with 18FDG-PET or integrated PET-CT for nodule
characterisation has been performed.
STUDY DESIGN
The SPUtNIk trial is a multicentre prospective cohort
observational study designed to (1) assess the diagnostic
performances of DCE-CT and 18FDG-PET-CT for the
characterisation of SPNs in the National Health Service
(NHS) setting and (2) use decision analytic modelling
to assess the likely costs and health outcomes resulting
from incorporation of DCE-CT into management strat-
egies for patients with SPNs. Secondary objectives
include assessment of the incremental value of incorpor-
ating the CT appearances of a SPN into the interpret-
ation of integrated PET-CT examinations and assessing
whether combining DCE-CT with 18FDG-PET-CT is more
accurate and/or cost-effective for characterising SPNs
than either test used alone or in series. The study con-
sists of a cohort of 375 patients and the full protocol is
available as an online supplementary material.
The primary inclusion criterion is the presence of a
dominant indeterminate soft tissue SPN identiﬁed on
CT that measures ≥8 and ≤30 mm on axial plane (with
no ancillary evidence strongly indicative of malignancy)
which is being considered for further evaluation with
18FDG-PET-CT. Potential participants will be identiﬁed
either at local multidisciplinary meetings or at time of
referral for investigation of a SPN. The study involves a
single DCE-CT (radiation dose 25 mSv) being per-
formed in addition to the patient’s standard SPN man-
agement. The DCE-CT is performed within 21 days of
the 18FDG-PET-CT examination. Exclusion criteria
include history of malignancy within 2 years, conﬁrmed
aetiology of the SPN at the time of the qualifying CT,
biopsy of the nodule before the DCE-CT, contraindica-
tion to potential surgical resection or radiotherapy and
contraindication to any of the imaging investigations.
Site accreditation and quality assessment for
18FDG-PET-CT and DCE-CT will be performed using
established procedures by the PET core laboratory at St
Thomas’ Hospital, London and Mount Vernon Hospital,
London, respectively. The 18FDG-PET-CT and DCE-CT
image acquisition and data analysis will follow a standar-
dised protocol. The 18FDG-PET-CT images and attenu-
ation correction CT images will initially be classiﬁed
according to a ﬁve-point characterisation scale. Further
quantitative analysis will consist of measurements of
FDG uptake expressed as the maximum standardised
uptake value. The diagnostic performance of
18FDG-PET will be assessed with and without incorpor-
ation of the CT appearances. The presence of incidental
extrathoracic ﬁndings on PET-CT will also be recorded.
DCE-CT interpretation will be performed by thoracic
radiologists at each participating site. For both DCE-CT
and PET-CT, central review of 10% of cases will be per-
formed by an expert radiologist/nuclear medicine phys-
ician to ensure quality assurance.
Following PET-CT and DCE-CT examinations subse-
quent SPN management is determined by the local spe-
cialist lung multidisciplinary meeting. The reference
standard will comprise pathological and/or imaging
follow-up data at 24 months. All patients without deﬁni-
tive pathological ﬁndings will undergo repeat CT exami-
nations of the chest at 3, 9 and 24 months (with or
without biopsy) in accordance with Fleischner guide-
lines. Clinical information, including information relat-
ing to costs will be extracted using a standardised data
collection form to inform the economic analysis. A suba-
nalysis using the BTS guidelines algorithm will also be
undertaken.
In parallel with the main study, a quantitative substudy
(IPCARD-SPN: validated in a population of general prac-
titioner referred chest radiograph attendees) will aim to
(1) identify the positive and negative predictive values of
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symptoms that distinguish between malignant and non-
malignant SPN and (2) ascertain whether or not the
inclusion of symptoms found to distinguish between
malignant and non-malignant nodules increases the
diagnostic value of DCE-CT and 18FDG-PET-CT.
TRIAL OUTCOME MEASURES
Primary outcome measures will include diagnostic test
characteristics (sensitivity, speciﬁcity, accuracy) for
18FDG-PET-CT and DCE-CT in relation to a subsequent
clinical diagnosis of lung cancer. The outcome measures
used in the economic model will include accuracy, esti-
mated life expectancy and quality-adjusted life years
(QALYs). Costs will be estimated from an NHS perspec-
tive. Incremental cost-effectiveness ratios will compare
management strategies with DCE-CT to strategies
without DCE-CT, where DCE-CT is expected to cost less
than half that of 18FDG-PET-CT.
Secondary outcome measures will include diagnostic
test characteristics for 18FDG-PET-CTwith incorporation of
CT appearances and combined DCE-CT/18FDG-PET-CT.
The incidence of incidental extrathoracic ﬁndings on
18FDG-PET/CT, subsequent investigations and costs will
also be determined.
Recruitment will be terminated when 375 patients have
been recruited and undergone DCE-CT. The study has two
possible end points for each patient: either the diagnosis of
lung cancer via biopsy or a diagnosis of benign or non-lung
cancer via either biopsy or failure of the imaged nodule to
progress (increase in size) during the 2-year follow-up
period. The end of the study will be reached when the last
study patient reaches either of these two end points or with-
draws full consent for continuing in the study.
CONCLUSIONS
With the potential adoption of a CT-based lung cancer
screening programme in the UK, the number of patients
with a SPN requiring further investigation could increase
substantially. Furthermore, SPNs are a common ﬁnding
on CT examinations undertaken for diagnostic or
staging purposes. Novel cost-effective approaches to the
assessment of SPNs will be of value to the NHS.
This study will provide accurate data on the diagnostic
performances of DCE-CT and 18FDG-PET/CT in the
NHS for the characterisation of SPNs: the decision ana-
lytic modelling will assess the likely costs and health out-
comes resulting from incorporation of DCE-CT into
management strategies for patients with SPNs.
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